Our Story

Jonathan Sackner-Bernstein, MD

— 1 min read

This week Michael Hyland invited me to his podcast, Parkinson's Disease Education. We discussed the story of Right Brain Bio and how the science of Parkinson's and the pharmacology of RB-190 should make us optimistic. Michael brought up all the key issues in our conversation.

Here are some of the key parts of the conversation:

2:30 - my background and reason for shifting my professional focus from cardiology to Parkinson's disease

11:40 - the scientific foundation of our current approach to PD

14:50 - how I figured this out

19:50 - the impact of dopamine reduction therapy

25:00 - update on the development program of RB-190

26:39 - I don't think levodopa causes toxicity

30:49 - possible clinical effects of dopamine reduction therapy

33:42 - the next steps for RB-190 and Right Brain Bio

We'll continue to share our progress in pursuit of our mission to conquer Parkinson's.

Share This

Sign up at: ParkinsonsDisease.blog

About Jonathan Sackner-Bernstein, MD

Dr. Sackner-Bernstein shares his pursuit of conquering Parkinson's, using expertise developed as Columbia University faculty, FDA senior official, DARPA insider and witness to the toll of PD.
Dr. S-B’s Linkedin page

RightBrainBio, Inc. was incorporated in 2022 to develop tranformative therapies for people with Parkinson's.